24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
Are Disinfectants Putting Nurses at Risk of COPD?Fat Collects in Lungs, Raising Asthma RiskDrug Limits Damage of Brain InjuryMore Patients With Heart Disease Die at Home Than in HospitalYour Noisy Knees May Be Trying to Tell You SomethingHealth Tip: 10 Ways to Reduce Injury RiskIs That Statin Doing You Any Good?Surgery Helps Tough-to-Treat Acid RefluxBrain Damage From Concussion Evident a Year LaterFor Kids With Genetic Condition, Statins May Be LifesaversNext-Gen Artificial Pancreas Boosts Blood Sugar ControlAHA News: Lowering Blood Pressure May Prevent New Brain Lesions in Older PeopleBladder Drug Can Cause Eye Damage: StudyGood News, Bad News on Concussions in High School SportsSteroid Shots for Painful Joints May Make Matters WorseHealth Tip: Broken Toe CareSleep Apnea Linked to Diabetic Eye DiseaseChildhood Risk Factors Can Predict Adult ObesityHealth Tip: Gum Disease Risk FactorsPut Safety First When Planning to Pack Food-to-GoA Parent's Guide to Managing Kids' Asthma During the FallWhat Foods Are Most Likely to Cause Acne Breakouts?Vision Problems Strike More Than 2 Billion GloballyLight Smoking Causes More Lung Damage Than Once Suspected: StudyHealth Tip: Choking First AidBy Mid-Century, Heat Waves Could Cover Far Bigger AreasGet Vaccinated Before Flu Takes Hold: CDCClose to 1,300 Cases of Vaping-Linked Illness Now IdentifiedMore Years of Football, Higher Odds for Brain Disease LaterPain Relief: When to Use Cold, When to Use HeatAHA News: High Triglycerides Caused a Diet Change – at Age 10Humans May Possess Ability to Regrow CartilageHealth Tip: Recognizing Bedbug Bites'Smartphone Slouching' More Serious Than It SoundsAHA News: What's Your Sense of Purpose? The Answer May Affect Your HealthDeep Brain Stimulation May Relieve Ringing in the Ears: StudyWhat Are the Risks of Pain Relief Alternatives to Opioids?Many ICU Admissions May Be Preventable, Large Study SuggestsCause of Paralyzing Illness in Kids Remains ElusiveFlu Season Is Coming: Here's How to Protect YourselfSinus Infections: What You Need to KnowFewer Teeth, Higher Risk of Heart Disease?Fungal Invasion May Drive Some Pancreatic CancersHealth Tip: Lowering Your Resting Heart RateYour Washer Might Be Breeding Drug-Resistant GermsCan Your Eating Habits Keep Alzheimer's at Bay?Prescription Opioids Linked to Poor Outcomes in Kidney PatientsCases of Serious Vaping-Linked Lung Injury Now Top 1,000Organic Chicken Less Likely to Harbor a Dangerous 'Superbug'Running the Numbers on High Blood Pressure
Questions and AnswersLinks
Related Topics

Diabetes

Common Diabetes Drug May Also Shield Kidneys, Heart

HealthDay News
by -- Robert Preidt
Updated: Apr 15th 2019

new article illustration

MONDAY, April 15, 2019 (HealthDay News) -- A common diabetes drug may also greatly reduce the odds for death from kidney failure and heart disease in diabetes patients with kidney disease, a new study finds.

The news on Invokana (canagliflozin) is important, experts say, because diabetes and kidney trouble so often go together.

"Diabetes is the leading cause of kidney failure worldwide, but for almost two decades there have been no new treatments to protect kidney function," noted study lead author Vlado Perkovic. He's a professor at The George Institute for Global Health at Oxford University in the United Kingdom.

"This definitive trial result is a major medical breakthrough as people with diabetes and kidney disease are at extremely high risk of kidney failure, heart attack, stroke and death," Perkovic said in a university news release. "We now have a very effective way to reduce this risk using a once daily pill."

The research was paid for by drug company Janssen, which makes Invokana. The study involved more than 4,400 patients with diabetes and kidney disease across 34 countries. Half took Invokana and half took a "dummy" placebo pill. All of them received care for kidney disease according to current guidelines.

Those who took Invokana had a 30% lower risk of developing kidney failure, a 30% lower risk of dying from kidney failure or heart disease, a 20% lower risk of major heart events such as heart attack, stroke, or heart-related death, and a 39% lower risk of hospitalization for heart failure, the researchers reported.

The findings were published April 15 in the New England Journal of Medicine.

There was no higher risk of major side effects among those who took Invokana, according to the study, which was also due to be presented Monday at the ISN World Congress of Nephrology, in Melbourne, Australia.

Invokana is from a class of diabetes medicines known as sodium glucose transporter 2 (SGLT2) inhibitors.

Study co-author Meg Jardine, associate professor at The George Institute, said, "With 5 million people worldwide predicted to have kidney failure by 2035, this is a major breakthrough."

Two experts in diabetes and renal (kidney) care who read over the new study agreed the findings are significant.

"Upwards of 40% of end-stage renal disease patients have diabetes as the cause of their renal failure," noted Dr. Maria DeVita, chief of nephrology at Lenox Hill Hospital in New York City.

She explained that SGLT2 inhibitor medicines like Invokana work by blocking the "reuptake" of glucose within the kidney. More of this blood sugar, as well as salt, are therefore excreted harmlessly in urine instead of lingering in the kidneys where they can do damage, DeVita said.

So, Invokana "may substantially change the trajectory of kidney decline, preserving kidney function for years longer than we thought possible for the long term," DeVita said. "This is wonderful news for those with diabetic kidney disease."

Dr. Guy Mintz directs cardiovascular health at the Sandra Atlas Bass Heart Hospital in Manhasset, N.Y. He also believes the new findings are "exciting."

"With another impressive study of this family of medications, SGLT2 inhibitors should now be utilized in all type 2 diabetic patients with kidney disease and increased cardiovascular risk," as long as there are no reasons not to do so, Mintz believes.

"This is another tool in our belt to reduce progressive kidney disease and cardiac events in our type 2 diabetic population with kidney disease," he said.

More information

The National Kidney Foundation has more on diabetes and kidney disease.